Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), filed a Form 4 on October 28, 2026, disclosing a same-day option exercise and sale of common stock on October 26, 2026, executed under a pre-established 10b5-1 trading plan.

Key Highlights

  • Option exercise: Mancini acquired 2,310 shares of common stock on October 26, 2026, via a stock option exercise at a price of $33.62 per share (transaction code M).
  • Same-day sale: Mancini disposed of 2,310 shares on October 26, 2026, at a price of $186.99 per share (transaction code S).
  • 10b5-1 plan: Both transactions were made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
  • Remaining direct ownership: Following the transactions, Mancini directly holds 39,765 shares, which according to the filing includes 39,575 restricted stock units.
  • Derivative securities: Mancini retains 91,315 stock options (right to buy) with an exercise price of $33.62 and an expiration date of April 1, 2035.
  • Vesting schedule: The option vests 25% on the first anniversary of April 1, 2025, then 1/48th monthly thereafter, fully vesting on the fourth anniversary of that date, subject to continued service.

Mancini's October 2026 Option Exercise and Share Sale at Revolution Medicines

According to the filing, Anthony Mancini, identified as Chief Global Commercialization Officer of Revolution Medicines, Inc., reported two transactions in the company's common stock on October 26, 2026. First, he exercised a stock option to acquire 2,310 shares at the exercise price of $33.62 per share. Immediately following, he sold those same 2,310 shares at $186.99 per share. The filing states that both transactions were carried out pursuant to a Rule 10b5-1 trading plan that Mancini adopted on June 11, 2026.

Prior to the reported transactions, Mancini held 42,075 shares directly. After the exercise and sale, his direct beneficial ownership stands at 39,765 shares, which the filing notes includes 39,575 restricted stock units. The filing was signed by Jack Anders as attorney-in-fact for Anthony Mancini on October 28, 2026.

In Table II, the filing discloses that Mancini held 91,315 stock options following the reported transactions, down from 106,109 options before the exercise. These options carry an exercise price of $33.62 and an expiration date of April 1, 2035. The filing describes the vesting schedule as 25% on the first anniversary of April 1, 2025 (the "Vesting Commencement Date"), with 1/48th vesting monthly thereafter, so that all shares are fully vested on the fourth anniversary of the Vesting Commencement Date, subject to the reporting person's continued service through each vesting date.

What Was Disclosed

Revolution Medicines officer Anthony Mancini filed a Form 4 reporting a 10b5-1 plan-based exercise of 2,310 stock options at $33.62 and a same-day sale of those shares at $186.99 on October 26, 2026, leaving him with 39,765 directly held shares and 91,315 remaining options.